Yael Flamand
Papers
1
Total Citations
100
H-Index
1
About
Yael Flamand is a leading clinical researcher in head and neck oncology, with a primary focus on de-escalation strategies for HPV-related oropharynx cancer. Her most influential work stems from the landmark ECOG-ACRIN E3311 trial, which investigated whether patients with p16-positive oropharynx cancer could safely receive reduced postoperative radiation doses after transoral robotic surgery. This study, cited over 100 times, demonstrated that lowering adjuvant intensity-modulated radiotherapy (IMRT) from 60 Gy to 50 Gy did not compromise two-year progression-free survival in intermediate-risk patients. Flamand’s contributions have directly shaped evolving treatment paradigms, helping to minimize long-term toxicity without sacrificing oncologic outcomes. Her research sits at the critical intersection of surgical innovation and radiation de-escalation, offering patients a path toward less morbid care. Beyond E3311, her work continues to influence clinical trial design in head and neck cancer, particularly in refining risk stratification and personalizing adjuvant therapy. For students and researchers, Flamand exemplifies how rigorous trial design can translate into meaningful, patient-centered advances in oncology.
Research Focus
Key Achievements
Top Papers
- 1